Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Abstract MOUNTAINEER was a multicenter, open-label, phase 2 trial (NCT03043313) that evaluated the efficacy and safety of tucatinib plus trastuzumab, a dual HER2-targeted chemotherapy-free regimen. Patients were included if they had chemotherapy-refractory, HER2+, RAS wild-type unresectable or metas...

Descripción completa

Detalles Bibliográficos

Autores principales:	John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz-Josef Lenz, Kristen Ciombor, Elena Elez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Mina Nayeri, Wentao Feng, Mark Bieda, Tanios S. Bekaii-Saab
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2026-01-01
Colección:	Nature Communications
Acceso en línea:	https://doi.org/10.1038/s41467-025-67824-z
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!